Dysregulation of leukocyte gene expression in women with medication-refractory depression versus healthy non-depressed controls

BMC Psychiatry

Alan R Light⁴  Lowry Bushnell²  Timothy A VanHaitsma³  Ronald W Hughen¹  Andrea T White³  Howard R Weeks²  Scott C Tadler¹  Kathleen C Light¹  Eli Iacob⁴ 

[1] Department of Anesthesiology, University of Utah Health Sciences Center, Salt Lake City, UT, USA;Department of Psychiatry, University of Utah, Salt Lake City, UT, USA;Department of Exercise and Sport Science, University of Utah, USA, Salt Lake City, UT, USA;Neuroscience Program, University of Utah Health Sciences Center, Salt Lake City, UT, USA

关键词: Oxytocin;    Amyloid precursor protein;    Transient vanilloid receptor;    Purinergic receptor;    Immune;    Gene expression;    qPCR;    Females;    Medication-refractory;    Bipolar disorder;    Depression;   

Others  :  1123921
DOI  :  10.1186/1471-244X-13-273

 received in 2013-05-29, accepted in 2013-10-07,  发布年份 2013

【 摘 要 】

Background

Depressive Disorders (DD) are a great financial and social burden. Females display 70% higher rate of depression than males and more than 30% of these patients do not respond to conventional medications. Thus medication-refractory female patients are a large, under-served, group where new biological targets for intervention are greatly needed.

Methods

We used real-time quantitative polymerase chain reaction (qPCR) to evaluate mRNA gene expression from peripheral blood leukocytes for 27 genes, including immune, HPA-axis, ion channels, and growth and transcription factors. Our sample included 23 females with medication refractory DD: 13 with major depressive disorder (MDD), 10 with bipolar disorder (BPD). Our comparison group was 19 healthy, non-depressed female controls. We examined differences in mRNA expression in DD vs. controls, in MDD vs. BPD, and in patients with greater vs. lesser depression severity.

Results

DD patients showed increased expression for IL-10, IL-6, OXTR, P2RX7, P2RY1, and TRPV1. BPD patients showed increased APP, CREB1, NFKB1, NR3C1, and SPARC and decreased TNF expression. Depression severity was related to increased IL-10, P2RY1, P2RX1, and TRPV4 expression.

Conclusions

These results support prior findings of dysregulation in immune genes, and provide preliminary evidence of dysregulation in purinergic and other ion channels in females with medication-refractory depression, and in transcription and growth factors in those with BPD. If replicated in future research examining protein levels as well as mRNA, these pathways could potentially be used to explore biological mechanisms of depression and to develop new drug targets.

【 授权许可】

   
2013 Iacob et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Thase ME: Bipolar depression: diagnostic and treatment considerations. Dev Psychopathol 2006, 18(4):1213-1230.
• [2]Little A: Treatment-resistant depression. Am Fam Physician 2009, 80(2):167-172.
• [3]Piccinelli M, Wilkinson G: Gender differences in depression. critical review. Br J Psychiatry 2000, 177:486-492.
• [4]Goswami DB, May WL, Stockmeier CA, Austin MC: Transcriptional expression of serotonergic regulators in laser-captured microdissected dorsal raphe neurons of subjects with major depressive disorder: sex-specific differences. J Neurochem 2010, 112(2):397-409.
• [5]Szewczyk B, Albert PR, Burns AM, Czesak M, Overholser JC, Jurjus GJ, Meltzer HY, Konick LC, Dieter L, Herbst N, et al.: Gender-specific decrease in NUDR and 5-HT1A receptor proteins in the prefrontal cortex of subjects with major depressive disorder. Int J Neuropsychopharmacol 2009, 12(2):155-168.
• [6]Guilloux JP, Douillard-Guilloux G, Kota R, Wang X, Gardier AM, Martinowich K, Tseng GC, Lewis DA, Sibille E: Molecular evidence for BDNF- and GABA-related dysfunctions in the amygdala of female subjects with major depression. Mol Psychiatry 2012, 17(11):1130-1142.
• [7]Lin YM, Ko HC, Chang FM, Yeh TL, Sun HS: Population-specific functional variant of the TPH2 gene 2755C>A polymorphism contributes risk association to major depression and anxiety in Chinese peripartum women. Arch Womens Ment Health 2009, 12(6):401-408.
• [8]Wang L, Liu L, Shi S, Gao J, Liu Y, Li Y, Zhang Z, Wang G, Zhang K, Tao M, et al.: Cognitive trio: relationship with major depression and clinical predictors in Han Chinese women. Psychol Med 2013, 43:1-11.
• [9]Belzeaux R, Formisano-Treziny C, Loundou A, Boyer L, Gabert J, Samuelian JC, Feron F, Naudin J, Ibrahim EC: Clinical variations modulate patterns of gene expression and define blood biomarkers in major depression. J Psychiatr Res 2010, 44(16):1205-1213.
• [10]Iga J, Ueno S, Yamauchi K, Motoki I, Tayoshi S, Ohta K, Song H, Morita K, Rokutan K, Ohmori T: Serotonin transporter mRNA expression in peripheral leukocytes of patients with major depression before and after treatment with paroxetine. Neurosci Lett 2005, 389(1):12-16.
• [11]Mehta D, Menke A, Binder EB: Gene expression studies in major depression. Curr Psychiatry Rep 2010, 12(2):135-144.
• [12]Cattaneo A, Gennarelli M, Uher R, Breen G, Farmer A, Aitchison KJ, Craig IW, Anacker C, Zunsztain PA, McGuffin P, et al.: Candidate Genes Expression Profile Associated with Antidepressants Response in the GENDEP study: differentiating between baseline ‘predictors’ and longitudinal ‘targets’. Neuropsychopharmacology 2013, 38(2):376.
• [13]Kawamura Y, Liu X, Akiyama T, Shimada T, Otowa T, Sakai Y, Kakiuchi C, Umekage T, Sasaki T, Akiskal HS: The association between oxytocin receptor gene (OXTR) polymorphisms and affective temperaments, as measured by TEMPS-A. J Affect Disord 2010, 127(1–3):31-37.
• [14]Saphire-Bernstein S, Way BM, Kim HS, Sherman DK, Taylor SE: Oxytocin receptor gene (OXTR) is related to psychological resources. Proc Natl Acad Sci U S A 2011, 108(37):15118-15122.
• [15]Thompson RJ, Parker KJ, Hallmayer JF, Waugh CE, Gotlib IH: Oxytocin receptor gene polymorphism (rs2254298) interacts with familial risk for psychopathology to predict symptoms of depression and anxiety in adolescent girls. Psychoneuroendocrinology 2011, 36(1):144-147.
• [16]Cyranowski JM, Hofkens TL, Frank E, Seltman H, Cai HM, Amico JA: Evidence of dysregulated peripheral oxytocin release among depressed women. Adv Psychosom Med 2008, 70(9):967-975.
• [17]Scantamburlo G, Ansseau M, Geenen V, Legros JJ: Intranasal oxytocin as an adjunct to escitalopram in major depression. J Neuropsychiatry Clin Neurosci 2011, 23(2):E5.
• [18]Ozsoy S, Esel E, Kula M: Serum oxytocin levels in patients with depression and the effects of gender and antidepressant treatment. Psychiatry Res 2009, 169(3):249-252.
• [19]Catena-Dell'Osso M, Fagiolini A, Marazziti D, Baroni S, Bellantuono C: Non-monoaminergic targets for the development of antidepressants: focus on neuropeptides. Mini Rev Med Chem 2013, 13(1):2-10.
• [20]Matsuzaki M, Matsushita H, Tomizawa K, Matsui H: Oxytocin: a therapeutic target for mental disorders. J Physiol Sci 2012, 62(6):441-444.
• [21]Light AR, Bateman L, Jo D, Hughen RW, Vanhaitsma TA, White AT, Light KC: Gene expression alterations at baseline and following moderate exercise in patients with Chronic Fatigue Syndrome and Fibromyalgia Syndrome. J Intern Med 2012, 271(1):64-81.
• [22]Coryell MW, Wunsch AM, Haenfler JM, Allen JE, Schnizler M, Ziemann AE, Cook MN, Dunning JP, Price MP, Rainier JD, et al.: Acid-sensing ion channel-1a in the amygdala, a novel therapeutic target in depression-related behavior. J Neurosci 2009, 29(17):5381-5388.
• [23]Kittner H, Franke H, Fischer W, Schultheis N, Krugel U, Illes P: Stimulation of P2Y1 receptors causes anxiolytic-like effects in the rat elevated plus-maze: implications for the involvement of P2Y1 receptor-mediated nitric oxide production. Neuropsychopharmacology 2003, 28(3):435-444.
• [24]Micale V, Cristino L, Tamburella A, Petrosino S, Leggio GM, Drago F, Di Marzo V: Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology 2009, 34(3):593-606.
• [25]Smolin B, Karry R, Gal-Ben-Ari S, Ben-Shachar D: Differential expression of genes encoding neuronal ion-channel subunits in major depression, bipolar disorder and schizophrenia: implications for pathophysiology. Int J Neuropsychopharmacol 2012, 15(7):869-882.
• [26]Pereira VS, Casarotto PC, Hiroaki-Sato VA, Sartim AG, Guimaraes FS, Joca SR: Antidepressant- and anticompulsive-like effects of purinergic receptor blockade: Involvement of nitric oxide. Eur Neuropsychopharmacol 2013. doi:10.1016/j.euroneuro.2013.01.008. [Epub ahead of print]
• [27]Sperlagh B, Csolle C, Ando RD, Goloncser F, Kittel A, Baranyi M: The role of purinergic signaling in depressive disorders. Neuropsychopharmacol Hung 2012, 14(4):231-238.
• [28]Zhang L, Su TP, Choi K, Maree W, Li CT, Chung MY, Chen YS, Bai YM, Chou YH, Barker JL, et al.: P11 (S100A10) as a potential biomarker of psychiatric patients at risk of suicide. J Psychiatr Res 2011, 45(4):435-441.
• [29]American Psychiatric Association APATFoDSMIV: Diagnostic and statistical manual of mental disorders: DSM-IV-TR. Washington, DC: American Psychiatric Association; 2000.
• [30]Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62.
• [31]Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967, 6(4):278-296.
• [32]Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, et al.: The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003, 54(5):573-583.
• [33]Hernandez ME, Mendieta D, Martinez-Fong D, Loria F, Moreno J, Estrada I, Bojalil R, Pavon L: Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder. Eur Neuropsychopharmacol 2008, 18(12):917-924.
• [34]Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H: Cytokine production and treatment response in major depressive disorder. Eur Neuropsychopharmacol 2000, 22(4):370-379.
• [35]Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H: Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997, 9(11):853-858.
• [36]Hannestad J, DellaGioia N, Bloch M: The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Eur Neuropsychopharmacol 2011, 36(12):2452-2459.
• [37]Kenis G, Maes M: Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol 2002, 5(4):401-412.
• [38]Drzyzga L, Obuchowicz E, Marcinowska A, Herman ZS: Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun 2006, 20(6):532-545.
• [39]Schatzberg AF, Lindley S: Glucocorticoid antagonists in neuropsychiatric [corrected] disorders. Eur J Pharmacol 2008, 583(2–3):358-364.
• [40]Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK: A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006, 63(8):856-864.
• [41]Miller AH, Maletic V, Raison CL: Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009, 65(9):732-741.
• [42]Blume J, Douglas SD, Evans DL: Immune suppression and immune activation in depression. Brain Behav Immun 2011, 25(2):221-229.
• [43]Messay B, Lim A, Marsland AL: Current understanding of the bi-directional relationship of major depression with inflammation. Biol Mood Anxiety Disord 2012, 2(1):4.
• [44]Padmos RC, Hillegers MH, Knijff EM, Vonk R, Bouvy A, Staal FJ, de Ridder D, Kupka RW, Nolen WA, Drexhage HA: A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch Gen Psychiatry 2008, 65(4):395-407.
• [45]Simon NM, McNamara K, Chow CW, Maser RS, Papakostas GI, Pollack MH, Nierenberg AA, Fava M, Wong KK: A detailed examination of cytokine abnormalities in major depressive disorder. Eur Neuropsychopharmacol 2008, 18(3):230-233.
• [46]Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctot KL: A meta-analysis of cytokines in major depression. Biol Psychiatry 2010, 67(5):446-457.
• [47]Slattery DA, Neumann ID: Oxytocin and Major Depressive Disorder: Experimental and Clinical Evidence for Links to Aetiology and Possible Treatment. Pharmaceuticals (Basel) 2010, 3:702-724.
• [48]Heinrichs M, von Dawans B, Domes G: Oxytocin, vasopressin, and human social behavior. Front Neuroendocrinol 2009, 30(4):548-557.
• [49]van Londen L, Goekoop JG, van Kempen GM, Frankhuijzen-Sierevogel AC, Wiegant VM, van der Velde EA, De Wied D: Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology 1997, 17(4):284-292.
• [50]Jakobsson J, Zetterberg H, Blennow K, Johan Ekman C, Johansson AG, Landen M: Altered Concentrations of Amyloid Precursor Protein Metabolites in the Cerebrospinal Fluid of Patients with Bipolar Disorder. Neuropsychopharmacology 2012, 38(4):664-72.
• [51]Hock C, Golombowski S, Muller-Spahn F, Naser W, Beyreuther K, Monning U, Schenk D, Vigo-Pelfrey C, Bush AM, Moir R, et al.: Cerebrospinal fluid levels of amyloid precursor protein and amyloid beta-peptide in Alzheimer's disease and major depression - inverse correlation with dementia severity. European neurology 1998, 39(2):111-118.
• [52]Pomara N, Bruno D, Sarreal AS, Hernando RT, Nierenberg J, Petkova E, Sidtis JJ, Wisniewski TM, Mehta PD, Pratico D, et al.: Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder. Am J Psychiatry 2012, 169(5):523-530.
• [53]Baba H, Nakano Y, Maeshima H, Satomura E, Kita Y, Suzuki T, Arai H: Metabolism of amyloid-beta protein may be affected in depression. J Clin Psychiatry 2012, 73(1):115-120.
• [54]Sun X, Mwamburi DM, Bungay K, Prasad J, Yee J, Lin YM, Liu TC, Summergrad P, Folstein M, Qiu WQ: Depression, antidepressants, and plasma amyloid beta (Beta) peptides in those elderly who do not have cardiovascular disease. Biol Psychiatry 2007, 62(12):1413-1417.
• [55]Moon YS, Kang SH, No HJ, Won MH, Ki SB, Lee SK, Kim do H: The correlation of plasma Abeta42 levels, depressive symptoms, and cognitive function in the Korean elderly. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(7):1603-1606.
• [56]Manna SS, Umathe SN: A possible participation of transient receptor potential vanilloid type 1 channels in the antidepressant effect of fluoxetine. Eur J Pharmacol 2012, 685(1–3):81-90.
• [57]Light AR, White AT, Hughen RW, Light KC: Moderate exercise increases expression for sensory, adrenergic, and immune genes in chronic fatigue syndrome patients but not in normal subjects. J Pain 2009, 10(10):1099-1112.
• [58]Lucae S, Salyakina D, Barden N, Harvey M, Gagne B, Labbe M, Binder EB, Uhr M, Paez-Pereda M, Sillaber I, et al.: P2RX7, a gene coding for a purinergic ligand-gated ion channel, is associated with major depressive disorder. Hum Mol Genet 2006, 15(16):2438-2445.
• [59]Green EK, Grozeva D, Raybould R, Elvidge G, Macgregor S, Craig I, Farmer A, McGuffin P, Forty L, Jones L, et al.: P2RX7: A bipolar and unipolar disorder candidate susceptibility gene. Am J Med Genet B Neuropsychiatr Genet 2009, 150B(8):1063-1069.
• [60]Skaper SD, Debetto P, Giusti P: The P2X7 purinergic receptor: from physiology to neurological disorders. FASEB J 2010, 24(2):337-345.
• [61]Keystone EC, Wang MM, Layton M, Hollis S, McInnes IB: Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann Rheum Dis 2012, 71(10):1630-1635.
• [62]Gao ZG, Jacobson KA: Emerging adenosine receptor agonists: an update. Expert Opin Emerg Drugs 2011, 16(4):597-602.
• [63]Hassel B, Tauboll E, Shaw R, Gjerstad L, Dingledine R: Region-specific changes in gene expression in rat brain after chronic treatment with levetiracetam or phenytoin. Epilepsia 2010, 51(9):1714-1720.
• [64]Choi KH, Higgs BW, Weis S, Song J, Llenos IC, Dulay JR, Yolken RH, Webster MJ: Effects of typical and atypical antipsychotic drugs on gene expression profiles in the liver of schizophrenia subjects. BMC Psychiatry 2009, 9:57.
• [65]Kalman J, Palotas A, Juhasz A, Rimanoczy A, Hugyecz M, Kovacs Z, Galsi G, Szabo Z, Pakaski M, Feher LZ, et al.: Impact of venlafaxine on gene expression profile in lymphocytes of the elderly with major depression–evolution of antidepressants and the role of the “neuro-immune” system. Neurochem Res 2005, 30(11):1429-1438.
• [66]Iga J, Ueno S, Yamauchi K, Numata S, Kinouchi S, Tayoshi-Shibuya S, Song H, Ohmori T: Altered HDAC5 and CREB mRNA expressions in the peripheral leukocytes of major depression. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31(3):628-632.